JAK Inhibitor

ApprovedSmall molecule

FFred Hutchinson Cancer Center

JAK Inhibitor is one of 256 small molecule programs targeting Myelofibrosis. It is currently in Approved.

Indications

Total Trials

Active Trials

255

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyelofibrosisActive, not recruiting

DermatitisActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Aicardi-Goutières SyndromeActive, not recruiting

DermatomyositisActive, not recruiting

MyelofibrosisPhase 2

Active, not recruiting

DermatitisPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Interstitial Lung DiseasePreclinical

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

Ulcerative ColitisPreclinical

Active, not recruiting

Aicardi-Goutières SyndromePreclinical

Active, not recruiting

DermatomyositisApproved

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

JAK Inhibitor

FFred Hutchinson Cancer Center

Approved

1 2

Rituxan

Roche

Preclinical

61 3

Cimzia

UCB

Preclinical

30 4

Simponi

Johnson & Johnson

Preclinical

19 5

Enbrel

IImmunex

Preclinical

64 6

Remicade

OOrganon and Co

Preclinical

43 7

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 8

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 9

Rituxan

Pfizer

Preclinical

7 10

Velcade

SShilpa Grover, MD, MPH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

Interstitial Lung Disease

NCT07406932

Q3 2029

Phase 2Recruiting

Myelofibrosis

NCT04370301

Q3 2030

Phase 2Recruiting

Myelodysplastic Syndrome

NCT07228624

Clinical

Trials by Indication[1]

Interstitial Lung Disease1 trial

A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

Not yet recruiting·—·N/A·NCT07406932·80 enrolled

Myelofibrosis1 trial

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04370301·20 enrolled

JAK Inhibitor1 trial

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors

Unknown status·LLiga Panamericana de Asociaciones de Reumatologia (PANLAR)··NCT04821206·3,000 enrolled

Dermatomyositis1 trial

The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 4·NCT04966884·20 enrolled

Rheumatoid Arthritis1 trial

The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients

Withdrawn·AAbu Dhabi Stem Cells Center·Phase 3·NCT05379322

4 more indications

Aicardi-Goutières syndrome1 trial

Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome

Completed·IIRCCS Fondazione Stella Maris··NCT06898372·24 enrolled

Dermatitis1 trial

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Recruiting·SShixiu Wu·Phase 2·NCT06715982·35 enrolled

Myelodysplastic Syndrome1 trial

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07228624·50 enrolled

Ulcerative Colitis1 trial

The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis

Recruiting·HHumanitas Clinical and Research Center··NCT06691061·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for JAK Inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JAK Inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JAK Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fred Hutchinson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFred Hutchinson Cancer Center

JAK Inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2029

Q3 2030

Trials by Indication[1]

Interstitial Lung Disease1 trial

Myelofibrosis1 trial

JAK Inhibitor1 trial

Dermatomyositis1 trial

Rheumatoid Arthritis1 trial

Aicardi-Goutières syndrome1 trial

Dermatitis1 trial

Myelodysplastic Syndrome1 trial

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News